BioXel Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but the offering is valued up to $ 69.0 million. The company intends to list its shares on the Nasdaq under the symbol BTAI.
The underwriters for the offering are Barclays, UBS Investment Bank and BMO Capital Markets.
This is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.
The firm’s drug re-innovation ap…
24/7 Wall St.